I. FUNCTIONALIZATION OF CRYTPOHANE CAGES FOR XENON MRI II. VANADIUM CATALYZED OXIDATIVE COUPLING OF SP\u3csup\u3e3\u3c/sup\u3e C – H BONDS TO HETEROARENES by Simone, Marissa
University of Rhode Island 
DigitalCommons@URI 
Open Access Master's Theses 
2014 
I. FUNCTIONALIZATION OF CRYTPOHANE CAGES FOR XENON 
MRI II. VANADIUM CATALYZED OXIDATIVE COUPLING OF SP3 C – 
H BONDS TO HETEROARENES 
Marissa Simone 
University of Rhode Island, msimone@chm.uri.edu 
Follow this and additional works at: https://digitalcommons.uri.edu/theses 
Recommended Citation 
Simone, Marissa, "I. FUNCTIONALIZATION OF CRYTPOHANE CAGES FOR XENON MRI II. VANADIUM 
CATALYZED OXIDATIVE COUPLING OF SP3 C – H BONDS TO HETEROARENES" (2014). Open Access 
Master's Theses. Paper 468. 
https://digitalcommons.uri.edu/theses/468 
This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion 
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, 
please contact digitalcommons@etal.uri.edu. 
I. FUNCTIONALIZATION OF CRYTPOHANE 
CAGES FOR XENON MRI 
II. VANADIUM CATALYZED OXIDATIVE 
COUPLING OF SP3 C – H BONDS TO 
HETEROARENES  
BY 
MARISSA SIMONE 
 
 
 
 
 
A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE 
IN 
CHEMISTRY 
UNIVERSITY OF RHODE ISLAND 
2014
  
MASTER OF CHEMISTRY THESIS 
 
OF 
 
MARISSA C. SIMONE 
 
 
 
 
 
 
 
 
 
 
 
APPROVED:  
 
Thesis Committee: 
 
Major Professor  Brenton DeBoef 
 
Mindy Levine 
 
Al Bach 
 
Nasser H. Zawia 
  DEAN OF THE GRADUATE SCHOOL 
 
 
 
 
 
 
 
UNIVERSITY OF RHODE ISLAND 
2014
  
ABSTRACT 
The lack of resolution and selectivity in current imagining techniques such as x-
ray, optical, and magnetic resonance imaging (MRI) has excelled the development of 
new biosensor technologies. Cryptophane A, a molecular cage composed of two 
cyclotriveratrylene (CTV) units connected by alkoxy bonds, can be turned into 
biosensors by attaching a target moiety capable of binding to a particular analyte. 
Cryptophanes can encapsulate xenon making it an attractive biosensor candidate for 
detection by hyperpolarized xenon-129 (HP-129Xe) MRI. Further detection 
enhancement is achieved by using a technique called hyperpolarized chemical exchange 
saturation transfer (HYPER-CEST). One of the key challenges in developing Xe-
biosensors is the need for water soluble cryptophanes and their attachment to 
biomolecules that specifically bind physiological targets.  
The first manuscript entitled “Functionalization of Cryptophane cages for Xenon 
MRI” discusses the synthesis of cryptophane cages and their potential to be further 
functionalized. The manuscript centers on synthesizing cryptophanes that are water 
soluble functionalized with gold nanoparticles, which can eventually be further 
modified for imaging molecular events in vivo.  
The second manuscript, “Vanadium Catalyzed Oxidative Coupling of sp3 C-H 
Bonds to Heteroarenes” discusses oxidative aminomethyaltion of imdizolpyridines.  
This manuscript proposes a vanadium catalyzed oxidative coupling of imidazopyridines 
with N-methylmorpholine oxide which serves as both sp3 hybridized coupling partner 
and the oxidant.  The reaction was optimized and performed with a variety of substrates 
  
to yield on a library of aminomethylated products. We investigated the mechanism and 
propose that a Mannich-type mechanism is responsible for the formation of the product. 
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PREFACE 
The following work is presented in manuscript format according to the 
guidelines presented by the University of Rhode Island Graduate School. This thesis 
will consist of two manuscripts that are currently in the process of publication. 
Manuscript 1 entitiled, “Functionalization of Cryptophane Cages for 129Xe 
MRI” will be submitted to Bioorganic and Medicinal Chemistry Letters in December 
2014.  
Manuscript 2 entitled, “Vanadium Catalyzed Oxidative Coupling of sp3 C–H 
Bonds to Heteroarenes” will be submitted to Organic Letters for publication in 
November 2014.   
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INTRODUCTION 
 
The ability to make a definitive medical diagnosis and follow the onset of certain 
diseases is vital in treating patients. Current imaging techniques, such as CT, PET, and 
MRI, possess different limitations that lower their overall effectiveness (Table 1). 1 
Computed tomography, a non-invasive imaging method, generates an image by using 
X-rays that are absorbed by tissues.2 Though inexpensive, CT is incapable of molecular 
imaging and exposure to hazardous X-ray radiation renders CT a less attractive method 
for imaging. Positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) are capable of anatomical and molecular imaging. 
These techniques are advantageous as there are no depth detection limits, short temporal 
resolutions, no perturbation of biological systems, and they require very low doses of 
the probe molecules.  However, both techniques lack spatial resolution, require 
exposure to harmful radiation and are very costly.1   
Imaging 
Technique 
Image 
generation  
Spatial 
Resolution 
Temporal 
resolution 
Type of 
probe used 
Principal 
Use 
CT X-rays 50-200 
mm 
10 secs to 
mins 
N.A. Anatomical  
PET γ-rays 1-2 mm Minutes Radio 
labeled 
Gene 
expression 
SPECT γ-rays 1-2 mm Minutes Radio 
labeled 
Gene 
expression 
MRI radiowaves 50-500 
mm 
Minutes 
to hours 
Paramagnetic Physiological, 
anatomical  
 Table 1: Characteristics of different imaging techniques1  
Magnetic resonance imaging (MRI) is widely used for scanning deep tissue in 
the diagnosis of human diseases. Though this technique allows for high spatial 
resolution, only a small percentage of hydrogen nuclei align with the magnetic field, 
rendering this technique inherently insensitive. To increase signal intensity, contrast 
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agents, such as gadolinium or iron oxide-based particles are often employed. These 
contrast agents work by changing the T1 and T2 relaxation times of water, thereby 
enhancing signal intensity.3  However, recent findings suggest that development of 
nephrogenic systemic fibrosis (NSF) in patients can be triggered by the administration 
of gadolinium agents.4  Other MRI contrast agents such as manganese and lanthanides, 
are toxic even at low concentrations and interfere with neuronal functions by blocking 
ion-channels.5 As a result, the need for non-toxic and non-proton MRI contrast agents 
needs to be explored. These issues may be circumvented by incorporating the inert noble 
gas xenon-129 (129Xe) as a molecular probe, since it is not present in the body, it is non-
toxic, and it can be hyperpolarized to enhance its sensitivity. Herein, the use of xenon-
129 in MRI, its ability to be hyperpolarized, Hyper-CEST techniques that allow for 
better detection, and the utilization of water soluble cryptophanes as hosts for Xe will 
be discussed.  
Hyperpolarized Xenon 
  Xe exists as two NMR active isotopes, a spin-1/2 nucleus 129 Xe and spin-3/2 
nucleus 131Xe. Only the former is capable of being hyperpolarized.6  The ability to 
hyperpolarize 129Xe is advantageous, as it allows for a 10,000-times signal enhancement 
as a result of the alignment of more nuclear spins with the magnetic field. Where typical 
proton MRI has only a 15 ppm chemical shift range, 129Xe has range over 200 ppm, 
which allows for chemical shift imaging.7 Solubility of xenon in lipid-rich tissue and 
blood allows for imaging of brain, lung and other regions.8   
 Spin exchange optical pumping (SEOP) is a three-step process used to 
hyperpolarize 129Xe. The first step involves the generation of circular polarized light by 
 3 
 
a Ti:sapphire laser (Figure 2).  In the second step, a droplet of Rb is heated in a glass 
cell, while exposed to a magnetic field, to produce a vapor, which then absorbs circular 
polarized light, driving the selective excitation of the D1 transition state. The third step 
produces hyperpolarized 129Xe. When polarized Rb collides with 129Xe, it transfers the 
spin of its valence electron to the 129 Xe nucleus. As a result of this dipole interaction, 
xenon is now predominately in the state that is aligned with the external magnetic field. 
9 Once hyperpolarized (HP) 129Xe is achieved, it can be delivered in vivo to be imagined. 
 
Figure 1:  SEOP set up 9 
The delivery of HP -129Xe to the body can be achieved through inhalation or 
injection.  Inhalation of hyperpolarized 129Xe permeates through lung tissue and blood, 
allowing for exploration of certain high concentration of characteristics of lung 
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function.10   Studies have shown that inhalation of HP- 129Xe results in highly spatially 
resolved images (Figure 2). Typical 1H MRI is not a viable option for evaluation of 
patients with chronic obstructive lung disease (COPD) or asthma as it is not capable of 
imaging lungs, due to their low proton density (Figure 2 left). While using HP-129 Xe 
in MRI yields an image that allows for distinction between lung airspaces in patients 
with COPD and asthma, rendering HP-129Xe superior  to 1H MRI. 11 
 
Figure 2: MRIs of a subject with COPD and asthma, left: 1H MRI, right: HP-129Xe 
MRI. 11 
   The polarization lifetime of 129Xe is dependent on its molecular environment. 
In oxygenated blood T1 = 13 s, deoxygenated blood T1 = 4 s, and T1 ≈ 100 s in deuterated 
saline solution.6 While long polarization lifetimes are advantageous, they require longer 
time for imaging, which still does not result in optimal detection. Use of a host for 129Xe 
allows for targeted imaging of molecular events.  Such targeted molecular imaging via 
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129Xe MRI is usually accomplished by employing molecular probes that contain cage-
shaped structures that are capable of encapsulating xenon atoms.  The most common 
molecular cage that is used for this task is called cryptophane A. 
Cryptophanes 
Cryptophanes are molecular cages composed of two cyclotriveratrylenes 
(CTVs) that are connected by alkoxy linkers (Figure 3).12 The lipophilic character of 
cryptophane’s cavity allows for reversible binding of small, non-polar molecules, like 
xenon.  
 
Figure 3: a) Cryptophane A, b) cryptophane 3,3,3, c) cryptophane 1,1,1, d) 
cryptophane TAAC, and TTPC.11,13, 14 
The affinity and exchange rate of xenon depends on the cavity size of the 
cryptophane, which is varied by changing the number of carbons in the alkoxy linkers 
that join the two CTVs (Table 2).  As the cavity size of cryptophanes decreases, there 
is an increase in the xenon binding constant.15 While large binding constants are 
advantageous, the development of new detection techniques require the in and out 
exchange to be fast, and therefore, 129Xe should not be so tightly bound.9  
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Cryptophane Cavity Size 
(Å3) 
Binding constant 
(M-1) 
kin (s-1) kout (s-1) 
(1.1.1) 81 10,000 n.d 2.4 
A (2,2,2) 95 3900 50 25 
E (3,3,3) 121 10 n.d n.d 
TAAC A (2.2.2) 95 17,300 n.d n.d 
TTPC n.d 33,000 n.d n.d 
Table 2: Properties of cryptophanes11,12,13 
When 129Xe is bound in the cavity of a cryptophane cage, it produces a unique 
chemical shift distinct from free 129Xe in the 129Xe NMR spectra. The typical chemical 
shift of Xe@cryptophane complexes is demonstrated in Figure 4, where the larger the 
cavity size, the more the peak corresponding to encapsulated 129Xe is shifted up-field.6 
This trend is broken by Xe@cryptophane-1,1,1 with a chemical shift of 31.1 ppm, 
whereas cryptophane A is at 65 ppm. It has been postulated this anomalous result is 
derived from the absence of methoxy groups, which suggests that modifying cages 
with electron withdrawing or donating groups can alter the chemical shift of 
Xe@cryptophanes. 6   Functionalizing cryptophanes with water solublizing groups, 
which are necessary for use in vivo, results in a higher binding affinity of 129Xe (Table 
2).13,15   
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Figure 4: 129Xe NMR spectra of water soluble cryptophanes 16 
One of the most promising applications of cryptophanes that encapsulate xenon 
is their ability create biosensors. This can be achieved by conjugating cryptophanes to 
a targeting ligand, which is capable of binding to a specific biological target, such as 
receptors on tumors or sites of inflammation. For example, Dmoschowiski recently 
synthesized a cryptophane that was tethered to the carbonic anhydrase (CA)-specific 
ligand, benzenesulfonamide.17 When the benzensulfanamide cryptophane binds to CA 
isozomes I or II, it produces a distinctive chemical shift from the biosensor when it is 
free in solution.6   Despite the synthesis of new water-soluble and ligand-ligand-
functionalized cryptophanes, more sensitive techniques for detection of HP- 129Xe needs 
to be addressed.  
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Hyper-CEST 
 Despite the high affinity of cryptophanes to bind 129 Xe, long acquisition times 
are necessary to achieve well-resolved spectra of bound 129Xe. This issue is 
circumvented by incorporating a method called chemical exchange saturation transfer 
(CEST) to enhance detection of hyperpolarized 129Xe, when used in conjunction with 
hyperpolarized 129Xe this technique is called Hyper-CEST. Xenon is an ideal candidate 
for this method due to its long relaxation times and large chemical shift difference 
between bound and free 129Xe.14  
 Instead of directly detecting the 129Xe that is bound in a cryptophane, 
HyperCEST detects the depletion of free 129Xe. In order to do this, an off- and on- 
resonance spectra is acquired. The off-resonance spectrum is a reference spectra 
obtained by applying a continuous wave saturation (Figure 5 A).  The on-resonance 
spectrum is obtained by applying a radio frequency pulse tuned to 129Xe@cryptopane 
signal (Figure 5 B).18 The difference of the on and off resonance spectra results in signal 
only arising from the depletion of the free 129Xe peak.19  The exchange of 129Xe from 
inside to outside the cryptophanes results in a reduction of the free 129Xe peak.  
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Figure 5: Depiction of Hyper-CEST: a) off -resonance spectra b) on-resonance 
spectra (modified from ref 18)18 
When hyperpolarized 129Xe (GREEN) enters the cage a radio frequency pulse 
pre-saturates the bound xenon causing removal of polarization (RED) (Figure 6).17  The 
depolarized 129Xe is then replaced by another polarized 129Xe atom through the natural 
in and out exchange. This cycle continues until there is an accumulation of depolarized 
129Xe.  
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Figure 6: Hyper-CEST process 17 
    
Dmochowski applied this technique to detect a water soluble cryptophane 
(Figure 3D) at concentrations as low as 1.4 pM.20  This indicates that HyperCEST 
should be an effective method for molecular imaging, as its detection limits are similar 
to those of PET and SPECT.  HyperCEST has recently been applied to multi-channel 
detection of cryptophane-A and perfluoroctyl bromide nanodroplets as they both act as 
hosts for 129Xe.18  
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MANUSCRIPT 1 
 
Efforts Towards Cryptophanes Functionalized with AuNPs 
Abstract 
 While advances in imaging have made it possible for the diagnosis of certain 
diseases, there are still many drawbacks.  This paper aims to discuss the use of 
hyperpolarized xenon in conjunction with gold nanoparticles that are decorated with as 
a novel probe for magnetic resonance imaging (MRI). The synthesis of cryptophanes, 
optimization of click reactions, and addition of gold nanoparticles will be discussed.  
General Introduction 
While conventional magnetic resonance imaging (MRI) allows for anatomical 
imaging, it is inherently insensitive due to the minimal amount of protons capable of 
aligning with the instrument’s magnetic field. Minimization of the signal to noise issues 
that are inherent in 1H MRI,  can be achieved by using 129Xe as a molecular probe, as it 
is not present in the body and has the ability to be hyperpolarized, thereby giving a 
10,000-times stronger signal.1   When 129Xe is encapsulated by a porous cage-shaped 
molecule, such as a cryptophane, a new signal, which is well resolved from the chemical 
shift of free 129Xe, is produced in the 129Xe NMR spectrum.  In principle, magnetic 
resonance imaging techniques can translate this unique signal into a high-resolution 3D 
image.  If these cryptophanes are attached to target-specific ligands, the cryptophane 
could serve as a biosensor, where its unique signal would be localized at a specific site 
within the body.  This cryptophane-ligand biosensor will allow for the specific detection 
of molecular processes or receptors.  
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Using hyperpolarized chemical exchange saturation transfer (HyperCEST) 
provides another source of signal amplification allowing for detection of sub-
micromolar concentrations of physiological targets. By selectively irradiating the 129Xe-
cryptophane signal, the loss of magnetization of the larger bulk Xe peak is easily 
detected.  This indirect detection method allows for very low detection limits, indicating 
that HyperCEST imaging could be used for true molecular imaging.1  Cryptophanes can 
be synthesized into biosensors by functionalizing cryptophanes with antibodies or 
peptide ligands that are capable of binding to specific targets in the body, such as 
enzymes. By doing this they are capable of being delivered to human cells and achieving 
concentrations that would allow for in vivo hyperpolarized 129Xe MRI studies. 2 Recent 
HyperCEST NMR experiments of water soluble triacetic acid cryptophane A have 
shown depolarization of 129Xe at a rate of 1.2x104 HP 129Xe atoms per second.3 This 
sensitive detection was performed at picomolar concentrations–a huge improvement 
over previous work at micromolar concentrations. 
Selective biosensors can be synthesized by functionalizing cryptophanes with 
antibodies or peptide ligands that are capable of binding to specific targets in the body, 
such as genes, receptors or enzymes. When the ligands on the biosensor bind to a 
specific target, a unique signal is produced allowing for detection of molecular events 
making it ideal for in vivo hyperpolarized 129Xe MRI studies. 2, 4  
Gold nanoparticles (AuNPs) are capable of being functionalized with a myriad 
of organic or biological ligands that bind selectively to small molecules or biological 
targets. This is achieved by varying the type of capping ligand used and fast or slow 
addition of NaBH4.
5 The use of gold nanoparticles in imaging has grown over the years 
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due to their unique optical properties. Along with the use of gold nanoparticles for 
various modes of imaging, they can be also used for drug delivery.7 For instance, Kim 
et al., developed multifunctional gold nanoparticles capable of anticancer therapy and 
computed tomography (CT) imaging of cancer cells.8 Further benefits of using gold 
nanoparticles is that they are nontoxic and non-immunogenic making them ideal drug 
delivery scaffolds.9  Therefore, tethering both cryptophanes and biological ligands to 
gold nanoparticles would allow for targeted imagining via HP-129Xe MRI.  
 
Scheme 1: Click reaction of cryptophane A to AuNPs (where n = # carbons) 
 
The use of gold nanoparticles to facilitate drug delivery and imaging when 
tethered to a cryptophane is unprecedented. The proposed study will focus on efforts 
towards synthesizing a biosensor consisting of a cryptophane tethered to gold 
nanoparticles via a thiol linker. The addition of protected thiol linkers to cryptophanes 
will be accomplished via the copper-catalyzed Huisgen cycloaddition, the so-called 
azide-alkyne click reaction (Scheme 1). After deprotection of the thiol group, gold 
nanoparticles capped with thiol ligands will be added to AuNPs that have been 
previously capped with labile thiol ligands.  These thiols will undergo ligand exchange 
with the thiols on the cryptophanes to yield the desired nanoparticles decorated with 
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cryptophanes.  The amount of cryptophane loaded onto the nanoparticle surface will be 
quantified by infrared spectroscopy. 
Cryptophanes and Gold Nanoparticles  
Over recent years, AuNPs have become increasingly popular in imaging due to 
their unique optical properties and ability to functionalize the surface with a myriad of 
organic compounds or biological ligands that selectively bind small molecules or 
biological targets.5  Additionally, gold nanoparticles are can be used as drug delivery 
vehicles, as gold nanoparticles have been shown to be non-toxic. Browen et al., achieved 
this by tethering the anti-cancer drug oxaliplatin to gold nanoparticles resulting in direct 
site drug delivery.6 
Tethering gadolinium (Gd) chelates to AuNPs has the capability to enhance the 
contrast signal in 1H MRI images. This enhancement is a result of the large number of 
Gd chelates on each AuNP, allowing for a more pronounced enhancement in contrast 
near the site of the AuNps.7 However, as previously discussed, the toxicity of Gd 
chelates renders them as less attractive modes of imaging. The capability to achieve 
signal enhancement utilizing gold nanoparticles initiated our investigation into 
developing AuNP-based 129Xe biosensors using a cryptophane.  
As originally reported by Dmochowski, the tripropargyl cryptophane-2,2,2 (2 
refers to the number of carbons in the alkoxy bridge between cage top and cage bottom), 
derivative can be accomplished in ten steps.4 The top of the cage, 1.3, was synthesized 
in three steps (Scheme 2). Vanily alcohol is protected with an allyl group in order to 
avoid polymerization in the cyclization step (Scheme 2).  Cyclization was achieved 
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through a Friedel-Crafts cyclization using HClO4 and MeOH. Deprotection of the allyl 
group required excess amounts of Pd/C and TsOH.  
 
Scheme 2: Synthesis of cage top  
 
Though the number of carbons in the propargyl linker can be varied, 
incorporating ethylene bridges results in a cryptophane cavity size that allows for 
optimal binding and exchange of 129Xe. Consequently, we set out to synthesize a 
cryptophane cage containing ethylene bridges between the two cyclotriveratrylenes. 
The linker containing the propargyl group was synthesized in five steps (Scheme 3). 
The first step, selective addition of the propargyl linker to the 3-position the linker 
starting material, 3,4 dihydroxybenzaldehyde was achieved using NaH and propargyl 
bromide. Though both phenols are deprotonated, position 4 is stabilized through 
resonance, therefore not as reactive as the 3 position (1.4). Subsequent steps included 
the addition of an ethylene linker (1.5), reduction of the aldehyde (1.6), a Finkelstein 
reaction (1.7) and finally, protection of the benzyl alcohol as a tetrahydropyranyl (THP) 
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ether (1.8). This protection step was necessary to avoid any unwanted side products in 
the final steps, and was easily removed in situ during the last step. Until recently, the 
majority of the aforementioned reactions required purification using flash 
chromatography, but we have recently developed recrystallization conditions that allow 
for easier scale-up of these synthetic steps. Recrystalization using hexanes and minimal 
amounts of ethyl acetate was implemented for the purification of 1.4, 1.5, and 1.6, 
resulting in analytically pure product. Since there is more of a possibility for side 
products during the first reaction, flash chromatography was kept as a purification 
procedure for the first step. When using recrystallization for the second step, a 77% 
yield was obtained, while using flash chromatography for the same step gave a 75% 
yield. Recrystallization for the reduction step resulted in comparable yields to when 
flash chromatography was used. Though similar yields were obtained, recrystallization 
is less time consuming and requires less solvent, so it became our preferred purification 
method.  
 
Scheme 3: Synthesis of propargyl linker 
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 Once the linker was synthesized, it was added in excess to the cage top and 
heated for two days under nitrogen at 55 ºC in the presence of the base, cesium carbonate 
(Scheme 4, 1.9). The final step in the synthesis of the conjugatable cryptophane (1.10) 
was the cyclization of the cage bottom, through a second Friedel-Crafts reaction, 
mediated by perchloric acid (Scheme 4). The overall yield of this synthesis is rather low 
due unwanted polymerization.  
 
Scheme 4: Synthesis of tripropargyl cryptophane A 
 The conversion of tri-propargyl Cryptophane A to a biosensor can be achieved 
via copper(I)-catalyzed Hugsien cycloaddition “click” of  a targeting moiety.2 Our aim 
was to decorate gold nanoparticles (AuNPs) with cryptophane cages, which potentially 
could increase the cryptophanes’ water solubility improving their applicability for in-
vivo imaging. Using gold nanoparticles also acts as a second scaffold to which 
biological ligands could be tethered.  
There are multitudes of ways to synthesize gold nanoparticles. For our purposes, 
the Brust-Schiffron method was the most attractive, as the resulting tiol capped AuNPs 
are easily re-dispersed in organic solvents, which we envisioned to be an advantage for 
subsequent modification reactions. Additionally, the dodecanethiol capping ligand used 
in the AuNP synthesis is known to readily undergo ligand exchange of a variety of 
thiols.5, 8 Copper(I) catalyzed azide-alkyne cycloaddition (CuAAC), click chemistry, 
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can be used to modify gold nanoparticles by employing an azide linker containing a 
thiol group.9  
The modification of AuNPs using click chemistry can be achieved via indirect 
and direct pathways. The indirect method involves synthesizing AuNPs with a 
dodecanethiol capping ligand that readily undergoes ligand exchange with a thiol-azide 
linker. At this point click chemistry using the appropriate conditions can be carried out 
between a cryptophane bearing alkyne groups, such as 1.10, and the azide-decorated 
AuNP.9a.9a The direct method involves carrying out the click reaction with a protected-
thiol-azide linker and a cryptophane like 1.10 in solution. Once completed, the thiol, 
which is now tethered to the cryptophane, can be deprotected and added as a capping 
ligand during the synthesis of AuNPs. Recent studies have found this method prevents 
aggregation of the consequent AuNPs.9a As a result, our initial attempts employed this 
method.   
 To carry out the click chemistry with the alkynes on cryptophanes, an azide-thiol 
linker needed to be synthesized. We attempted the synthesis of two azide-thiol linkers 
(Scheme 5).  In order to avoid poisoning of the copper catalyst and unwanted side 
products during the click reaction, the thiol group needed to be protected. This was 
achieved using trityl chloride to protect 2-aminoethanelthiol (1.11, Scheme 5) and 
acetate to protect mercaptopropionic acid (1.14). The synthesis of the azide portion of 
the two possible linkers was carried out by refluxing 3-bromopropionic acid or 2-
bromoethylamine with sodium azide.  Both reactions required extended reaction times 
and, unfortunately, were low yielding.  The synthesis of both azide-thiol linkers was 
then achieved using peptide-coupling conditions.   
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Scheme 5: Synthesis of protected thiol azide linkers.  
 
Previous click conditions utilized by Dmochowski, which required Cu2SO4, 
K2CO3, 2,6-lutidine and sodium ascorbic acid, did not result in any product and also are 
not compatible with gold nanoparticles, as salts cause the aggregation of gold 
nanoparticles.4  Therefore, new click conditions needed to be established and optimized. 
To achieve optimal yields when carrying out the click reaction with cryptophanes, the 
reaction was first optimized using the cryptophane linker, 1.5, with the thiol-azide 
linkers.   
Initially, copper sulfate pentahydrate and sodium ascorbic acid conditions were 
applied to click the trityl-thiol-azide linker (1.13) to 1.5 and eventually to tripropargyl 
cryptophane A, 1.10 (Scheme 4). Though yields were sufficient, the inability to 
deprotect the trityl group after the click reaction, resulting in the need to switch to the 
acetate protected thiol linker (1.16), in hopes that it would be easily deprotected. 
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Originally, the same conditions for the previous click reaction were applied to 
conjugate 1.16 to 1.5, however, no product was formed.  It is possible that the bulky 
trityl group on the thiol prevented the copper catalyst from coordinating with sulfur, 
whereas the thioacetate group may not hinder the poisoning of the catalyst. New click 
reactions involving copper(I) bromide [Cu(I)Br] and the hexabenzyltren (tren) ligand 
turned out to give better yields than the previously described conditions. Due to the air 
sensitivity of Cu(I)Br, these reactions were carried out in a Schlenk tube. The first 
conditions applied were using 1 equivalent of the alkyne, 1.5, and 1.1 equivalents of the 
azide, 1.16, with 30 mol% Cu(I)Br and the tren ligand, resulting in a 46% yield (Table 
1). Decreasing the mole percentage of Cu(I)Br and tren actually led to an increase in 
yield, though the reaction took 72 hr to complete.   Optimal reaction conditions were 
found to be 1 equivalent of 1.5, 1.1 equivalent of 1.16, 10 mol% Cu(I)Br  and tren ligand 
at 65 °C for 48 hr, giving a 64% yield (Table 1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
These optimal conditions were modified to achieve the click reaction at all three 
alkynes on the cryptophane. This was achieved by using 40 mol% Cu(I)Br and 40% tren 
Table 1: Optimization click conditions  
Entry 
1.5 
(equiv) 
1.16 
(equiv) 
Cu(I)Br Tren Ligand Solvent Conditions Yield 
1 1 1.1 30% 30% Toluene 
60 °C 
48 hr 
46% 
2 1 1 10% 10% Toluene 
60 °C 
72 hr 
54% 
3 1 1.1 10% 10% Toluene 
65 °C 
48 hr 
64% 
 25 
 
ligand. The solvent had to be changed from toluene, as cryptophane would not dissolve 
in it, to THF. This allowed for a tri-subsituted cryptophane with acetate-protected thiol 
linkers, 1.19, in a 59% yield (Scheme 6).  
 
Scheme 6: Click pathways to sulfur functionalized cages  
The next step involved deprotecting the acetate group. A multitude of different 
conditions were applied. Initial attempts involved refluxing 1.19 for three hours in 
hydrochloric acid and methanol.  When this did not work, thionyl chloride and then 
acetyl chloride conditions were applied. Neither of these worked and no starting 
material was recovered, leading us to believe that the product decomposed.  Basic 
conditions were then applied, using ethanol and sodium hydroxide or potassium 
hydroxide.  This did not work for the products of the click reaction, but it did work for 
the thioacetate linker (1.16).  The inability to deprotect the thiol, which was needed to 
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carry out the previously discussed direct method of functionalizing AuNPs, led us to 
explore the indirect method of AuNP functionalization. 
As previously mentioned, the indirect method involved ligand exchange of the 
dodecanethiol capping ligand with an thiol-azide chain. Deprotection of the trityl-thiol-
azide linker, 1.13, was achieved using TFA and triethylsilane in DCM. This was then 
added to AuNPs in DCM and stirred for two days at room temperature. The solution 
was concentrated and washed with ethanol to remove any free ligands.  Successful 
ligand exchange was verified by NMR (see supporting information). The click reaction 
between the azide-tethered AuNPs and cryptophane was performed using Cu(I)Br and 
the tren ligand. Unfortunately, the click reaction was not successful even with adding 
excess amounts of catalyst and extended reaction times.  
Another pathway to functionalize nanoparticles was attempted by performing 
ligand exchange between dodecanethiol capping ligand and 11-bromoundecylthiol, 
which was converted into an azide via an SN2 reaction with sodium azide. The formation 
of the azide-decorated AuNPs was verified via NMR, allowing for click chemistry to be 
carried out with tri-propargyl cryptophane using Cu(I)Br and tren ligand.  While the 
click reaction seemed to be successful, the AuNPs aggregated.  
Conclusion 
Future work involves using different deprotection strategies and/or protecting 
groups. Additional routes for AuNP functionalization could be accomplished by 
synthesizing a different cryptophane starting material by substituting one of the 
propargyl linkers in the cryptophane for a linker that is functionalized with thiol group.  
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Experimental Section 
 
Reagents 
All substrates and solvents were purchased from Sigma-Aldrich and Fisher Scientific. 
Flash chromatography was performed using hand columns or a Teledyne ISCO 
CombiFlashRf apparatus using RediSep Rf Silica gel (60 Å, 40-60 m). 
 
Instrumentation 
GC/MS analysis was carried out on an Agilent Technologies 6890 GC system fixed 
with a 5973 mass selective detector. NMR spectra were acquired with a Bruker 
Avance III 300 MHz spectrometer. 
 
 
Compound 1.1: 3-methoxy-4-(2-propenyloxy) benzenemethanol: 
 
Acetone, vanillyl alcohol (15.48 g, 97.29 mmol), and allyl bromide (12.94 g, 107.01 
mmol) were added to round bottom flask and stirred until homogeneous. K2CO3 (13.44 
g, 97.29 mmol) was added slowly and the mixture was refluxed overnight. The next 
day, the reaction was cooled to room temperature while stirring. Acetone was then 
removed under vacuum.  The resulting white residue was dissolved in 50 mL of DCM 
and 40 mL of H2O. The biphasic solution was transferred to a separatory funnel, and 
the aqueous layer was removed, and the organic layer was washed with 1 M NaOH (3 
x 50 mL) and brine (1 x 50 mL). The organic layer was collected, dried over MgSO4, 
filtered and the solvent was removed under vacuum to yield a yellow powder. 50 mL 
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of EtOAc was added, and then removed under vacuum (to remove excess allyl 
bromide), resulting in 1.1 (15.54 g, 82%) as a fine white powder. All spectral 
information matched literature values.1 
 
Compound 1.2: 2,7,12-Trimethoxy-3,8,13-tris(2-propenyloxy)-10,15-dihydro-5H-
tribenzo cycloononene 
 
 
 
In a round bottom flask equipped with a stir bar, 1.1 (4.91 g, 25.29 mmol) was 
dissolved in methanol (36 mL) and cooled to 0 °C in an ice bath. Perchloric acid (15 
mL) was added dropwise to the flask under N2.  The solution turned magenta while it 
stirred overnight.  The following day, DCM was added to the solution, and it was 
cooled again to 0 °C for 5 min. Then 32 mL of 5 M NaOH was added dropwise over 
10 min followed by the dropwise addition of saturated NaHCO3 (32 mL). The reaction 
was stirred at room temperature for 1-2 hours. The organic layer was then filtered, 
dried with MgSO4 and concentrated. Diethyl ether was added and the resulting 
suspension wad sonicated for 1 hr. The suspension was allowed to stir overnight at 
room temperature. The thickened product was isolated by filtration and the solid was 
dried under high vacuum to yield 1.2 (2.01 g, 15%) as an off -white solid. All spectral 
information matched literature values.1 
 
Compound 1.3 
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In a round bottom 1.2 (3.36 g, 6.34 mmol) was dissolved in THF (100 mL) and EtOH 
(68 mL) in a vacuum-dried flask under N2.  In a separate round bottom flask Pd/C 
(4.06 g, mmol) and TsOH (0.72 g, 4.22 mmol) was dissolved in 25 mL of H2O and 
then added to the other flask. The solution was heated to 75 °C for 2 days. Upon 
completion, the reaction was cooled to room temperature, and filtered over celite. The 
filtrate was concentrated and dissolved with THF and EtOAc. The organic solutions 
was washed 3x with 100 mL of saturated solution of NaHCO3 and 2x with 100 mL of 
brine. The organic layers were isolated, dried over MgSO4, and concentrated to 
dryness. The solid was then digested by stirring in chloroform for 1 hr.  The solid was 
filtered to obtain 1.3 (1.68 g, 35%) as a fine white powder. All spectral information 
matched literature values.1 
 
Compound 1.4: 3 propargyloxy-4-hydroxybenzaldehyde: 
 
 
 
 
To a flame dried 3-neck flask, NaH (0.96 g, 40 mmol) was added, followed by the 
addition of 20mL of DMSO in one portion, and was stirred until dissolved.  3,4- 
dihydroxy benzaldehyde (2.76 g, 20 mmol) was then dissolved in DMSO (12 mL) and 
was added all once at 0C. Once all aldehyde was added, the flask was removed from 
the ice bath, and propargyl bromide (2.37g, 20mmole) was added drop wise by 
syringe. The reaction was stirred overnight at room temperature. Reaction was poured 
over ice and neutralized with 1M HCl and extracted with EtOAc (3 x 75 mL). Organic 
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layers were washed with brine (3 x 50 mL), died over MgSO4, filtered, and the solvent 
was removed under pressure.  Flash chromatography to separated, using 20/80/1 of 
ethyl acetate/hexane/ glacial acetic acid. Pure product, 1.4 (2.60 g, 74%) was isolated. 
All spectral information matched literature values.1 
 
Compound 1.5 propargyloxy-4-(2-bromoethoxy)benzaldehyde: 
 
Added 1.4, propargyloxy-4-hydroxybenzaldehyde (1.65 g, 9.4 mmol), K2CO3 (6.00 g, 
46.9 mmol), and DMF to a three neck flask. Reaction was stirred at room temperature 
for 30 minutes. Dibromoethane (94 mmol, 6 mL) was then added in one portion and 
heated overnight at 60 °C under N2 atmosphere. Mixture was poured over 350 mL of 
water and was extracted using 3 x 10 mL (4 x 75mL) of ethyl acetate. Organic layers 
were washed with NaOH 1M (2 x 75 mL), H2O (75 mL), then brine (3 x 75 mL). 
Organic layer dried over MgSO4, filtered and solvent removed under vacuum. Using 
hexanes and minimal ethyl acetate product was recrystallized to give 1.5 (2.06 g, 77%) 
as a white solid. All spectral information matched literature values.1 
 
Compound 1.6 [3 propargyloxy-4-(2-bromoethoxy)phenyl]methanol 
 
 
To a three neck flask with N2 inlet, 1.5 (1.58 g, 5.60 mmol), was dissolved in 
methanol/THF solvent. Solution was cooled to -9°C in (MeOH/ice) followed by 
 34 
 
addition NaBH4 (0.25g, 6.70mmole). Mixture was stirred at 0°C for 20 min then 
allowed to warm to rt for an additional 40 min. Mixture was concentrated under 
vacuum and then cooled to 0 °C and acidified with 150 mL of dilute HCl. Sample was 
extracted with ethyl acetate (3 x 50 mL), then washed with brine (3 x 50 mL) and 
dried over MgSO4. Sample was filtered, and concentrated in vacuum and purified 
using recrystallization with hexanes to yield 1.6 (1.48g, 92%) as a white solid. All 
spectral information matched literature values.1 
 
Compound 1.7 [3 propargyloxy-4-(2-iodoethoxy)phenyl]methanol: 
 
 
 
In a round bottom flask, sodium iodide (4.86 g, 32.46 mmol) and 1.6 (2.30 g, 8.11 
mmol) were dissolved in acetone and refluxed overnight. Solvent was removed under 
vacuum and solid was dissolved in DCM and subsequently washed with sodium 
thiosulfate (2 x 50 mL), water (50 mL) and brine (2 x 50 mL). The organic layer was 
dried over MgSO4, filtered and solvent was removed under vacuum to yield pure 1.7 
(2.44 g, 98%) as a white solid. All spectral information matched literature values.1 
 
Compound 1.8 [3-propargyloxy-4-(2-iodoethoxy)phenyl]methanol:  
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In a three neck flask 1.7 (1.82 g, 5.48mmol) was dissolved in THF, to which DHP 
(0.55 g, 6.58 mmol) was then added. In a separate flask PPTS (0.13 g, 0.54 mmol) was 
dissolved in DCM and then added to main reaction flask. The reaction was stirred at 
room temperature overnight. Upon completion the reaction was concentrated under 
reduced pressure and subsequently diluted with EtOAc and washed with water and 
brine. It was then dried over MgSO4, filtered and concentrated by vacuum. The crude 
product was purified using flash chromatography with 20/80 EtOAc/Hexane. Product 
isolated to yield 1.8 (2.08 g, 91%) as yellow oil. All spectral information matched 
literature values.1 
 
Compound 1.9 
 
Cesium carbonate (1.27 g, 3.89 mmol) and 1.3 (0.26 g, 0.65 mmol) were added to a 
dried three neck flask with a stir bar and purged with nitrogen. Dry DMF was then 
added with a syringe and mixture was allowed to stir for 30 minutes at room 
temperature. Then using minimal amounts of DMF, 1.8 was added (1.07 g, 2.59 
mmol). The reaction was stirred under N2 at 65°C for 48 hours. Upon completion the 
reaction was cooled to room temperature and was poured into 100 mL of water. The 
aqueous layer was then extracted with 3 x 75 mL of EtOAc. Combined organic layers 
were washed with 3 x 100 mL of brine. The organic layer was isolated, dried over 
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MgSO4 and concentrated under vacuum. The crude product was purified by flash 
chromatography using 50/50, 60/40, and 75/25 EtOAc/Hex. Product was isolated and 
concentrated down to yield 1.9 (0.52 g, 63%). All spectral information matched 
literature values.1 
 
 
Compound 1.10 Tri-Propargyl Cryptophane A  
 
 
 
To a round bottom containing methanol (165 mL), 1.9 (0.21 g, 0.16 mmol) dissolved 
in DCM (5mL) was added. The reaction mixture was then cooled to 0°C and HClO4 
(165 mL) is added in a drop-wise fashion. Reaction was stirred at room temperature 
for 48 hrs. Upon completion the reaction was quenched with H2O (165 mL) and brine 
(165 mL) and stirred for 1 hour. Half of the mixture was extracted with 4 x 100mL of 
DCM, the organic layer is put aside and the second half of the reaction mixture was 
extracted with 4x100mL of DCM. Organic layers were combined and washed with 
H2O, saturated NaHCO3, and brine. Flash chromatography was performed using a 
gradient of DCM/Acetone 2%-10% to afford pure 1.10 (0.054g, 34%) as a white solid. 
All spectral information matched literature values.1  
 
Compound 1.11: 2-(tritylthio)ethanamine 
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To a round bottom containing thiol ethylamine (1 g, 8.8 mmol), TFA(6.3 mL) was 
added followed by the addition of trityl chloride (2.45 g, 8.8 mmol) and stirred at 
room temperature for three hours. The reaction was then concentrated, diluted with 
EtOAC, washed with 3N NaOH (4 x 15 mL), H2O (15 mL), and saturated NaHCO3 
(15 mL), and brine (15 mL). The organic layer was dried over MgSO4 and 
concentrated down. The reaction was recrystallized using DCM and hexanes yielding 
1.11 (2.68 g, 95%) as white solid.  All spectral information matched literature values.2 
 
Compound 1.12: 3-(azido)propionic acid 
 
Bromopropionic acid (1.52 g, 10mmol) was dissolved in acetonitrile (20 mL) and to it 
NaN3 (1.3 g, 20 mmol) was added. Reaction was refluxed overnight. Acetonitrile was 
removed under vacuum and resulting solid was dissolved in EtOAc (100 mL), washed 
with 0.1M HCl (3 x 60 mL), water (3 x 60 mL), and brine (100 mL). Organic layer 
dried with MgSO4 and concentrated down yielding 3-(azido)propionic acid, 1.12 
(0.50g, 43%) as a yellow oil. All spectral information matched literature values.3  
Compound 1.13:   
 
 
 
To a round bottom equipped with a stir bar, compounds 1.11 (1.16 g, 3.6 mmol), and 
1.12 (0.38 g, 3.3 mmol) were added. Followed by the addition of HBTU (1.50 g, 3.96 
mmol), round bottom was purged with N2 and then dry DCM (20 mL) was added 
followed by DIPEA (1.2 mL, 6.6 mmol). Reaction was stirred at room temperature, 
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under N2 for two days. Upon completion the reaction was washed with NaHCO3 (50 
mL) and brine (50 mL). Organic layer dried with MgSO4, filtered,  and concentrated 
down onto silica. The crude product was purified using a 20/80 - 70/30 solvent 
gradient of EtOAC/Hex. The product was isolated and concentrated down to yield 
1.13 (78%) as a white solid.  
1H NMR (300 MHz, CDCl3): δ 7.46 – 7.35 (Ar CH, m, 6H), 7.33 – 7.27 (Ar CH, m, 
6H), 7.25 – 7.19 (Ar CH m, 3H), 3.57 (COCH2, t, J = 6.5 Hz, 2H), 3.10 (-NHCH2, q, J 
= 6.1 Hz, 2H), 2.44 ( -N3CH2-, t, J = 6.3 Hz, 2H), 2.32 (SCH2- ,t, J = 6.5 Hz, 2H). 
13C NMR (75 MHz, CDCl3): δ 169.72, 144.65, 129.57, 128.06, 126.90, 66.90, 47.31, 
38.35, 35.67, 31.87. 
 
Compound 1.14: Propionicthioacetate  
 
Mercaptopropionic acid (1.4 mL 20mmol)  was added to NaOH (2 M) at 0°C. Acetic 
anhydride was then added and reaction was stirred for 30 minutes at 0°C. Reaction 
was acidified to a pH ≈2 with 6N HCl. Then the mixture was extracted with EtOAc (3 
x 30 mL). Organic layers were combined, dried with MgSO4, and concentrated down 
reduced pressure to yield 1.14 (2.68 g, 91%) as white crystals. All spectral information 
matched literature values.4  
Compound 1.15: 2-azidoethylamine 
 
Bromoethylamine (2.5 g, 12.20 mmol) was dissolved in 10 mL of water, followed by 
the addition of NaN3 (2.38 g, 36.36 mmol) and was refluxed for 21 hrs. Reaction was 
then cooled to 0°C and KOH (4g) was slowly added. The reaction mixture was then 
extracted using diethyl ether (3 x 10 mL) and organic layers were collected, dried over 
MgSO4 and concentrated until 10 mL was left (0.41g, 40%). All spectral information 
matched literature values. 5 
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Compound 1.16 
 
To round bottom containing 1.15 (0.67 g, 4.5mmol) and 1.14 (0.43 g, 5.00 mmol) 
were dissolved in DMF. EDC (2.96 g, 15.4 mmol) and HOBT (1.25 g, 8.19 mmol) 
were then added and the reaction was stirred at room temperature for two days. 
Reaction was diluted with water and extracted with DCM (3 x 50 mL). Organic layers 
were then washed with brine, isolated, dried over MgSO4, filtered and concentrated 
down. Purification was performed using flash chromatography (gradient of 
EtOAc/Hexane) to give pure  1.16, (0.42g 44%) as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ 5.92 (NH, s, 1H), 3.38 (d, J = 3.9 Hz, 4H), 3.08 (t, J 
= 7.0 Hz, 2H), 2.45 (t, J = 7.0 Hz, 2H), 2.27 (CH3-CO s, 3H). 
13C NMR (75 MHz, CDCl3): δ 196.21, 170.95, 50.85, 38.97, 36.20, 30.61, 24.85. 
 
Compound 1.17 
 
 
Tris (2 aminoethyl) amine (0.18 g, 1.3 mmol), phenylbenzylbromde (1.05 mL, 8.8 
mmol), and K2CO3 (1.90 g, 13.8 mmol), were refluxed in CH3CN under N2 for 48 hrs. 
Upon completion it was cooled on an ice bath and washed with acetonitrile, water, 
methanol and then dissolved in hot toluene. Toluene washed with brine and dried over 
MgSO4 and solvent was removed. Product was precipitated in methanol giving 1.17 
(0.69 g, 77%) as a yellow oil. All spectral information matched literature values.6   
 
 
Compound 1.18 
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To a vial equipped with a stir bar, 1.10 (0.11 g, 0.11mmol) and 1.13 (0.14 g, 0.33 
mmol) were dissolved in THF (5 mL). An aqueous solution of CuSO4 5H2O was 
added, followed by the slow addition of a freshly prepared aqueous solution of sodium 
ascorbic acid. Reaction was monitored by TLC (98%DCM/2%Acetone), upon 
disappearance of 1.10, THF was removed under vacuum.  
DCM and 3mL of concentrated NH3OH were added and stirred for 30 minutes. The 
organic layer was then washed with water and brine, dried over MgSO4 and filtered. 
Crude product was dried onto silica and purified using a 25 gram column (gradient of 
2/98-20/80 acetone/DCM) on the combi-fash. Product was isolated to yield 1.18 
(52%) as a white solid.   
1H NMR (300 MHz, CDCl3): δ 7.72 (tetrazole CH, s, 3H), 7.42 – 7.36 (m, 20H), 7.30 
– 7.19 (m, 32H), 6.81 (s, 3H), 6.77 (d, J = 1.4 Hz, 6H), 6.66 (s, 3H), 5.52 (-NH, t, J = 
5.7 Hz, 3H), 5.15 – 4.98 (-OCH2C, m, 6H), 4.67 (-COCH2, t, J = 6.4 Hz, 6H), 4.53 (-
OCH2CH2O-, dd, J = 13.6, 6.3 Hz, 6H), 4.17 (-ArCH2, s, 12H), 3.56 (-OCH3, s, 9H), 
3.37 (-OCH2CH2O-, dd, J = 14.2, 3.9 Hz, 6H), 3.03 (-NHCH2-, dt, J = 7.3, 3.6 Hz, 
6H), 2.75 (-NCH2-, t, J = 6.4 Hz, 6H), 2.40 (-CH2S-, t, J = 6.3 Hz, 6H). 
13C NMR (75 MHz, CDCl3): δ 168.85, 149.63, 148.37, 147.71, 146.52, 144.52, 
134.06, 133.23, 131.63, 129.47, 128.01, 126.87, 123.98, 121.65, 120.72, 117.99, 
114.46, 69.26, 66.93, 63.81, 56.03, 45.90, 38.33, 36.13, 31.64. 
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Compound 1.19 
 
 
 
 
To a Shlenk tube equipped with a stir bar, 1.10 (61 mg, 0.064 mmol), 1.16 (41 mg, 
0.19 mmol), and 1.17 (35 mg, 0.051 mmol) were added under N2 and dissolved in 2 
mL of THF. In the glove box Cu(I)Br (7.3 mg, 0.051mmol) was added to the Shlenk 
tube. The reaction was heated at 65°C for two days and monitored by TLC (2/98 
acetone/DCM), upon disappearance of 1.10, the reaction was worked up by removing  
THF under reduced pressure. Then DCM was added and the organic layer was washed 
with water and brine, dried over MgSO4, filtered and then dried onto silica for 
purification. Purified using 25 gram column and a gradient (2/98-20/80) of 
acetone/DCM on combi-fash. The product was isolated to yield 1.19 (59%) as a white 
solid.   
1H NMR (300 MHz, CDCl3): δ 7.60 (s, 3H), 6.80 (s, 3H), 6.69 (d, J = 13.4 Hz, 6H), 
6.59 (s, 3H), 6.12 (s, 2H), 5.15 – 5.00 (m, 6H), 4.49 (q, J = 6.7, 6.3 Hz, 12H), 4.12 (s, 
12H), 3.75 (d, J = 5.6 Hz, 6H), 3.56 (-OCH3, s, 9H), 3.32 (d, J = 13.7 Hz, 6H), 3.06 (t, 
J = 7.0 Hz, 7H), 2.42 (t, J = 6.9 Hz, 6H), 2.25 (-COCH3, s, 9H). 
13C NMR (75 MHz, CDCl3): δ 196.01, 171.30, 149.56, 148.29, 147.77, 146.45, 
134.10, 133.37, 131.68, 129.57, 123.70, 121.40, 120.58, 114.41, 69.20, 63.93, 56.07, 
49.71, 39.46, 36.11, 30.63, 24.76. 
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Compound 1.20: AuNPs 
  
  Gold nanoparticles were synthesized with dodecanethiol capping ligands using 
the Brust-Schiffrin “two-phase” method.7 An aqueous solution of HAuCl4 H2O (0.10 
g, 0.30 mmol) was mixed with tetraoctylammonium bromide (0.71 g, 1.31 mmol) in 
toluene. The solution was stirred vigorously until all of the gold was transferred into 
the organic layer. Dodecanethiol (0.055g, 0.27 mmol) was then added and stirred for 
20 mins, at which point the solution turned clear. An aqueous solution of NaBH4 (0.12 
g. 3.24 mmol) was slowly added and the resulting solution turned brown. The reaction 
was then stirred for 3 hrs at room temperature. The organic phase was then isolated 
and concentrated down to ~5 mL, which was then mixed with 200 mL of EtOH and 
kept at -18° C for 4 hours. The dark brown precipitate was then filtered off and re-
dissolved in 5 mL of toluene, which was then precipitated again using 100 mL EtOH. 
The suspension was then filtered and washed with copious amounts of EtOH to 
remove any free dodecane thiol, product was dried under vacuum overnight. 
Transmission electron miscopy validated the presence of AuNPs.  
 
Compound 1.21: Azide-AuNPs 
The 11-bomoundecylthioacetate (0.10 g, 0.32 mmol) was dissolved in 1 mL of 
ethanol. NaOH was added (0.1 mL) and reaction mixture was refluxed for 2 hrs. The 
reaction was then neutralized with 6 mL of 2 M HCl. The mixture was transferred to 
separatory funnel and then 10 mL of diethyl ether was added followed by the addition 
of with 5 mL of H2O. The organic layer was washed with 5 mL of H2O, isolated, dried 
of MgSO4 and then filter. The solvent was removed and product was left to dry under 
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vacuum overnight. The deprotected 11-bomoundecylthiol was then dissolved in DCM 
and added to AuNPs.  AuNPs functionalized with 11-bromoundecylthiol (28 mg) were 
dissolved in DCM (6 mL) and added to a solution of sodium azide (70 mg) in DMSO 
(6 mL). The solution was stirred for 2 days at room temperature. An IR was taken to 
verify the presence of an azide and once complete water was added and the organic 
layer was isolated. The AuNPs were washed with ethanol and then dried under 
vacuum to yield AuNPs-N3 (0.021 g). FTIR: 2094.06 cm
-1 
 
 
1H NMR spectra of compound 1.13 
 
 
 
 
 
13C NMR spectra of compound 1.13 
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1H NMR spectra of compound 1.16 
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13C NMR spectra of compound 1.16 
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1H NMR spectra of compound 1.18 
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13C NMR spectra of compound 1.18 
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COSY of 1.18 
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HMQC of Compound 1.18 
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1H NMR spectra of compound 1.19 
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Transmission Electron Microscopy (TEM) images of 1.20
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Transmission Electron Microscopy (TEM) images of 1.20
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MANUSCRIPT 2 
 
Vanadium Catalyzed Oxidative Coupling of sp3 C-H Bonds to Heteroarenes 
 
Abstract 
The vanadium-catalyzed oxidative coupling of substituted 2-phenyl-
imidiazo[1,2-a]pyridines to N-methylmorpholine which acts as the sacrificial oxidant 
has been achieved. This reaction was applied to various 2-phenyl-imidiazo[1,2-
a]pyridines substrates resulting in yields as high as 90%. 
Introduction 
 
Incorporating new carbon–carbon and carbon–nitrogen bonds into organic 
molecules is an apparent need in today’s chemical industry. There have been many 
recent advances in this field, most using metal catalysis, however most require pre-
functionalization steps and have poor atom economy.1 The ability to oxidatively couple 
two carbon hydrogen bonds (or carbon–hydrogen and nitrogen –hydrogen) to form a 
carbon-carbon bond (or carbon–nitrogen bond) with no pre-functionalization would be 
ideal.2  Incorporating C–N bonds via cross dehydrogenative coupling can be 
accomplished through direct oxidative amination or oxidative aminomethylation.   The 
direct formation of C–N bonds under oxidative conditions has been achieved through 
various methods.3 Ami-nomethylation is an alternative and convenient way to incor-
porate C–N bonds (Scheme 1). The less common oxidative aminomethylation is shown 
by Uang et al., who achieved oxidative aminomethylation of naphthalenes.5   Another 
example of aminomethylation is shown by Mitchel et al., who developed a method for 
installing N-methylmorpholine on imidazopyridines structures, a precursor to an active 
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pharmaceutical ingredient that could serve as a treatment of several myeloproliferative 
disorders.10   
 
There are numerous methods to oxidatively couple two sp2 hybridized carbons 
in high yields.2  The coupling of an sp3 to an sp2 hybridized carbon is much less common 
due to the less reactive nature of sp3 hybridized C–H bonds compared to that of sp2 ¬C–
H bonds.4 In order to achieve sp3 C–H bond activation, reactive directing groups are 
often needed.3 Another difficulty is the potential for β-hydride elimination after C–H 
activation of sp3 bonds.4 The oxidative coupling of a sp3 C–H bond to a sp2 C–H bond 
has received little attention,4,5,6,7 so there is still a great need to invent new ways of 
oxidatevly coupling sp3- sp2 carbon bonds in an efficient and green way.  
Pharmaceuticals such as necopidem, saripidem, and zolpidem contain a 
substituted imidazo[1,2-a]pyridines back bone (Figure 1).8  Providing a way to 
oxidatively couple the 3 position of 2-phenyl-imidazo[1,2-a]pyridine with alkyl 
derivatives would be a useful tool to have when synthesizing pharmaceuticals. This 
paper proposes a vanadium catalyzed oxidative coupling of imidazopyridines with N-
methylmorpholine oxide which serves as both sp3 hybridized coupling partner and the 
sacrificial oxidant. Using these conditions we were able to perform oxidative 
aminomethylation of imidazopyridines.  
Scheme 1- Amination vs Aminomethylation 
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Figure 1: Pharmaceuticals with imidazo[1,2-a]pyridines backbones 
 
  The synthesis of the starting material is accomplished in one step via an 
imminium formation followed by a nucleophlic cyclization (Scheme 2).9 The nature of 
the substituents on pyridine or bromoacetophenone did not greatly affect the starting 
material yields 1.  
 
Scheme 2: Synthesis of Starting Material 
 
Results and Discussion 
 
In order to achieve optimum conditions we screened solvent, catalys, catalyst 
loading, time, and equivalents of NMO. Ethanol, toluene, and tetrahydrofuran were 
initially tested as alternative solvents (Table 1 entries 4, 5, and 6). Nevertheless, none 
had comparable yields to methylene chloride.  The mole percent of vanadium (III) 
acetylacetonate, VO(acac)2 was varied from 25% to 10%,  showing that lower catalyst 
loading provided minimal impurities. To ensure that VO(acac)2 was the ideal catalyst 
to use we tested V2O5 ( entries 9,10.16 and 17).  While it eliminated the formation of the 
impurity, 3, it required longer reaction times and low amounts of NMO (entry 16), 
which still did not result in comparable yields to when VO(acac)2 was used under the 
same conditions (entry 14) .  The best yield was achieved using 10% of 
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(VO(acac)2), 5 equivalents of NMO for 6  hours in methylene chloride (entry 12). 
However by changing the solvent from methylene chloride to 1,4 - dioxane and 
increasing the catalyst loading VO(acac)2, we were able to avoid any of 3 from forming 
and achieve an 80% yield.  Performing a GC time study gave further insight into when 
the reaction would produce the least impurity (see Chart 1). The starting material was 
always present in small amounts as was 3. We stopped the reaction at 12 hours despite 
VO(acac)2 Time
Mol% (hrs)
1 25 10 DCM 18 59 3.7
2 10 10 DCM 18 68 0.3
3 20 10 DCM 18 62 2.7
4 20 10 Ethanol 18 33 1.5
5 20 10 Toluene 18 30 28.5
6 20 10 THF 18 57 1.3
7 20 10 DCM 18 68 2.2
8 20 5 DCM 18 68 10.7
9 20
b 5 DCM 5 58 15
10 20
b 5 DCM 4 31 14.9
11 10 5 DCM 18 72 4.6
12 10 5 DCM 6 88 5.8
13 20 5 Dioxane 12 80
c 0
14 20 3 DCM 18 69 18.7
15 20 3 DCM 4
incomplete 
conversion
--
16 20
b 3 DCM 18 57 0
17 20
b 1.2 DCM 18 36 5
18 20 1 DCM 18 52 34.2
(a) Product yield determined by NMR (b) V2O-5 used as catalyst (c) Actual yield
entry NMO Solvent
Product 
Yield 
a 3
Table 1- Optimization of the Reaction Conditions 
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the presence of starting material to avoid product decomposition. As such we decided 
to perform our substrate scope using entry 13 as our optimized conditions. 
Performing this reaction using substrates with electron withdrawing groups on 
the para position of the phenyl substituent resulted in less favorable yields or did not 
react. While electron donating groups in the para position lead to higher yields. Looking 
at the substrate scope (table 2) entry 10 has a nitro substituent in the para position 
resulted in no product while entry 8 with an ether substituent in the same position gave 
us an 84% yield.  The addition of a second electron donating substituent led to lower 
yields than only one electron donating group (4). Changing the position of the methyl 
group at C6 (entry 6) as to C8 (entry 7) gave a slightly higher yield. Yields varied with 
different halogens substituted at the phenyl para position.  For instance, a chlorine 
substituted phenyl ring had a much higher yield than when a bromine or fluorine was 
substituted in the same position. The addition of a methyl group at C7 on the Br para 
substituted ring gave a lower yield then fluorine. Methyl groups at the C6 position for 
both fluorine and chlorine substituted rings had high yields.  
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Table 2: Substrate Scope  
 
Previous studies of vanadium oxidative coupling of structures similar to 1 
propose a radical mechanism,10  while others theorize product is formed by way of a 
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Mannich-type reaction.5 We propose a Mannich type mechanism is responsible for the 
formation of our product (Scheme 4). This was determined by running a Mannich 
reaction using 1, formaldehyde, and morpholine to make the imminium in situ resulting 
in yields up to 98% (scheme 3).  Running our normal reaction conditions in the presence 
of TEMPO, a radical inhibitor, did not prevent product from forming further proving 
this reaction a Mannich-type mechanism is responsible.  
 
Scheme 3-Pure Mannich Conditions 
 
As such we believe the product is formed by the following mechanism (scheme 
4). The N- methyl morpholine oxidizes the VO(acac)2 catalyst resulting in the formation 
of the imminium ion. The vanadium species extracts a proton from 1 which then attacks 
the immionium ion forming our product 2. The elimination of water from vanadium 
regenerates the catalyst. We believe the main impurity is formed when the imminiom 
reacts with one of the ligands from the vanadium catalyst.  
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Scheme 4- Proposed mechanism of product and impurity 
 
Conclusions 
  
 The vanadium cataylzed oxidative coupling of substituted imidazole pyridines 
to nmethylmorpholene was achieved in yields up to 90%. Despite the ability to 
produce this product using true mannich conditions we believe this to useful method to 
demonstrate oxidative coupling.  
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Experimental Section 
 
Reagents 
All substrates were purchased from Sigma Aldrich and Fisher Scientific. Flash 
chromatography was performed using Teledyne ISCO CombiFlashRf Apparatus using 
RediSep Rf Silica gel (60 Angstroms, 40-60 microns). 
Instrumentation 
GC/MS analysis was carried out on an Agilent Technologies 6890 GC system fixed 
with a 5973 mass selective detector]. NMR spectra were acquired with a Bruker 
Avance III 300 MHz spectrometer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
General Synthesis of 2-phenyl- Imidazo[ 1,2-a] pyridines: 
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2-amino pyridine (1.3 g 13.8 mmol), 1-bromoacetophenone (2.19 g, 11.1 mmol), 
sodium bicarbonate (1.45 g, 17.25 mmol) and ethanol (9 ml) were added to a flask. A 
stir bar was added and the reaction was stirred at 60°C for 4hrs. The reaction was 
monitored by TLC at a 50:50 ethyl acetate: hexanes solvent system. After reaction was 
completed, the ethanol was rotavapped off, and 50mL of water was added in portions 
to dissolve the solid. The water was then extracted with two 50mL portions of ethyl 
acetate and dried with sodium sulfate. The filtrate was rotavapped off. A column was 
ran (80 g column on a gradient) to yield 1.66 g (78%) of product. All spectral 
information matched literature values.1 
Representative Procedure for Synthesis of substituted imidazole pyridines with 
N- methylmorpholene 
Imidazo[1,2-a]pyridine (1 mmol), NMO (5 mmol), VO(acac)2 (20 mol%), were 
dissolved in 1,4-dioxane (4 mL), and refluxed for 12 hrs. Upon completion the 
reaction was evaporated and diluted with water (10mL) and extracted with EtOAc 
(2x10mL). Organic layers were dried of Na2SO4 and concentrated. Purified by column 
chromatography using 4/1 EtOAc:Hex.  
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Characterization of Compounds: 
Characterization of Compound 2 
 
1H NMR (300 MHz, CDCl3): δ 8.43 (dd), 7.80 (m), 7.64(dt,), 7.46(m), 7.38 (m), 7.22 
(ddd), 3.98 (s), 3.67(t), 2.48 (t)  
13C NMR (101 MHz, CDCl3): δ 145.35, 145.10, 134.46, 128.87, 128.44, 127.74, 
125.29, 124.53, 117.29, 115.88, 111.85, 66.98, 53.19, 52.12. 
LRMS EI (m/z): [M+] calc’d for C18H19N3O 293.15, observed 293.10 
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Spectroscopic Data for Novel Compounds in Table 3: 
Characterization of Compound 3.4 
 
1H NMR (400 MHz, CDCl3): δ 8.42 (d,J =6.9 Hz, 1H) 7.70 (d, J=8.39 Hz, 2H), 
7.63(d, J=9.2hz, 1H), 7.27(d, J= 7.9 Hz, 2H), 7.24 – 7.17 (m, 1H), 6.82(t J=6.4 Hz, 
1H), 3.96(s, 2H), 3.67 (t, J=4.6 Hz, 4H), 2.48 (t, J=4.6Hz, 4H), 2.41 (s, 3H) 
13C NMR (101 MHz, CDCl3) δ 145.40, 145.04, 137.51, 131.55, 129.17, 128.17, 
125.24, 124.41, 117.20, 115.61, 111.75, 66.99, 53.19, 52.16, 21.28. 
LRMS EI (m/z): [M+] calc’d for C19H21N3O 307.17, observed 307.20  
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Characterization of Compound 3.5 
 
1H NMR (400 MHz, CDCl3): δ 8.51 (s, 1H), 7.69 (d, J= 8.0, 2H ), 7.53 (d, J=9.0, 
1H), 7.26 (d, J = 7.4, 2H), 7.06 (d, J = 9.3,1H), 3.93 (s, 2H),  3.67 (t, J=4.4 , 4H), 2.48 
(t, J=4.4, 4H), 2.40 (s, 3H), 2.37 (s,3H)  
13C NMR (101 MHz, CDCl3): 145.23, 144.10, 137.35, 131.73, 129.13, 128.66, 127.53, 
122.72, 121.31, 116.53, 115.36, 67.02, 53.20, 52.10, 21.27, 18.53. 
LRMS EI (m/z): [M+] calc’d for C20H23N3O 321.18, observed 321.20 
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Characterization of Compound 3.6 
 
1H NMR (300 MHz, CDCl3): δ 8.15, (s, 1H), 7.75 (d, J=8.72 Hz, 2H), 7.53 (d, J= 
9.55 Hz 1H), 7.08 (d, J=9.45 Hz, 1H), 7.00 (d, J=8.86 Hz, 2H), 3.92 (s,2H), 3.87 (s, 
3H), 3.69 (t, J= 4.47 Hz, 4H), 2.49 (t, J =4.49 Hz ,4H), 2.38 (s, 3H) 
13C NMR (75 MHz, CDCl3): δ 159.36, 143.87, 130.03, 127.84, 122.70, 121.59, 
121.00, 120.32, 116.35, 115.06, 113.93, 77.44, 67.01, 55.31, 53.20, 52.07, 18.54.  
LRMS EI (m/z): [M+] calc’d for C20H23N3O2 337.18, observed 337.20 
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Characterization of Compound 3.7 
 
1H NMR (400 MHz, CDCl3): δ 8.15 (s, 1H), 7.55 (d, J=9.2 Hz 1H), 7.33 – 7.41 (m, 
3H), 7.07 (d, J =9.2 Hz 1H), 6.92 (d, J = 7.5 1H), 3.94 (s, 2H), 3.88 (s, 3H), 3.68 (t, J = 
4.4 Hz, 4H), 2.50 (t, 4H), 2.38 (s, 3H) 
13C NMR (101 MHz, CDCl3): δ 159.67, 145.09, 144.10, 135.99, 129.36, 127.68, 
122.66, 121.49, 121.24, 116.65, 115.74, 113.86, 67.01, 55.34, 53.20, 52.01, 18.54. 
LRMS EI (m/z): [M+] calc’d for C20H23N3O2 337.18, observed 337.20 
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Characterization of Compound 3.8 
 
1H NMR (300 MHz, CDCl3): δ 8.13 (s, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.49 (s, 1H), 
7.37 (d, J = 8.3, 1H), 7.08 (d, J = 9.6 Hz, 1H), 6.96 (d, J = 8.2 Hz, 1H), 3.98 (s, 3H), 
3.94 (s, 3H), 3.70 (t, J = 4.4 Hz, 4H), 2.52 (t, J = 4.5 Hz, 4H), 2.39 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ 148.95, 148.76, 145.01, 143.95, 127.72, 127.32, 
122.47, 121.58, 121.11, 116.44, 115.19, 112.02, 110.95, 67.02, 55.99, 55.91, 53.23, 
52.04, 18.55. 
LRMS EI (m/z): [M+] calc’d for C21H25N3O3 367.19, observed 368.0 
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Characterization of Compound 3.9 
 
1H NMR (300 MHz, CDCl3):  δ 8.27 (d, J = 6.8 Hz, 1H), 7.44 (d, J = 1.9 Hz, 1H), 
7.39 – 7.29 (m, 1H), 7.02 (d, J =  7.0 Hz, 1H), 6.96 (d, J = 8.3 Hz, 7.6 Hz, 1H), 6.76 (t, 
J = 6.8 Hz, 1H), 3.98 (s, 3H), 3.94 (s, 3H), 3.93 (s, 2H), 3.68 (t, J = 4.5 Hz, 4H), 2.67 
(s, 3H), 2.50 (t, J = 4.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 148.95, 148.81, 145.27, 144.77, 127.34, 127.05, 
123.51, 122.82, 121.43, 115.83, 112.37, 112.03, 111.02, 67.01, 55.97, 55.94, 53.22, 
52.16, 17.18. 
LRMS EI (m/z): [M+] calc’d for C21H25N3O3 367.19, observed 367.20 
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Characterization of Compound 3.10 
 
1H NMR (400 MHz, CDCl3): δ 8.40 (d, J = 7.1 Hz, 1H), 7.81 – 7.74 (m, 2H), 7.64 (d, 
J = 9.06 Hz, 1H), 7.22 (t, J = 6.7Hz, 1H), 7.11 (m, 2H), 6.83 (t, J = 6.7 Hz, 1H), 3.93 
(s, 2H), 3.67 (t, J = 4.4 Hz, 4H), 2.47 (t, J = 4.4 Hz, 4H).  
13C NMR (101 MHz, CDCl3): δ 162.57 (JCF = 253 Hz), 145.07, 144.48, 130.63, 
130.53 (JCF = 9 Hz), 125.18, 124.67, 117.28, 115.42 (JCF 21 Hz), 115.32, 111.98, 
66.96, 53.20, 52.05. 
LRMS EI (m/z): [M+] calc’d for C18H18FN3O 311.14, observed 311.10  
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Characterization of Compound 3.11 
 
1H NMR (400 MHz, CDCl3): δ 8.13 (s, 1H), 7.81 – 7.74 (m, 2H), 7.51 (d, J = 9.2 Hz, 
1H), 7.16 – 7.09 (m, 2H), 7.06 (dd, J = 9.2, 1.7 Hz, 1H), 3.88 (s, 2H), 3.66 (t, J = 4.6 
Hz, 4H), 2.46 (t, J = 4.6 Hz, 4H), 2.36 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 162.50 (JCF = 245 Hz), 161.28, 144.32, 144.13, 
130.45 (JCF = 8 Hz), 127.79, 122.64, 121.57, 116.61, 115.51, 115.37 (JCF = 21 Hz), 
66.98, 53.20, 51.98, 18.53. 
LRMS EI (m/z): [M+] calc’d for C19H20FN3O 325.16, observed 325.20 
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Characterization of Compound 3.12 
 
1H NMR (400 MHz, CDCl3): δ 8.27 (d, J = 6.9 Hz, 1H), 7.80 – 7.72 (m, 2H), 7.36 (s,  
1H), 7.18 – 7.08 (m, 2H), 6.66 (dd, J = 7.1, 1.7 Hz, 1H), 3.89 (s, 2H), 3.65 (t, J = 4.6 
Hz, 4H), 2.45 (t, J = 4.4, 4H), 2.40 (s, 3H).  
13C NMR (101 MHz, CDCl3): δ162.4 (JCF = 250 Hz), 161.28, 145.49, 144.11, 135.64, 
130.45 (JCF = 9 Hz), 124.37, 115.55 (JCF = 20 Hz), 115.16, 115.26, 114.62, 66.97, 
53.17, 52.04, 21.34. 
LRMS EI (m/z): [M+] calc’d for C19H20FN3O 325.16, observed 325.20 
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Characterization of Compound 3.13 
 
1H NMR (400 MHz, CDCl3): δ 8.40 (d, J = 7.0, 1.2 Hz, 1H), 7.78 – 7.72 (m, 2H), 
7.62 (d, J = 9.0Hz, 1H), 7.45 – 7.39 (m, 2H), 7.22 (ddd, J = 9.2, 6.7, 1.3 Hz, 1H), 6.83 
(t, J = 6.9 Hz, 1H), 3.93 (s, 2H), 3.66 (t, J = 4.6 Hz, 4H), 2.46 (t, J = 4.6 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 145.13, 144.18, 133.74, 133.00, 130.06, 128.67, 
125.18, 124.77, 117.33, 116.07, 112.05, 66.93, 53.19, 52.02. 
LRMS EI (m/z): [M+] calc’d for C18H18ClN3O 327.11, observed 327.10 
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Characterization of Compound 3.14 
 
1H NMR (400 MHz, CDCl3): δ 8.14 (s, 1H), 7.78 – 7.74 (m, 2H), 7.52 (d, J = 9.2 Hz, 
1H), 7.43 – 7.38 (m, 2H) 7.07 (dd, J = 9.1, 1.7 Hz, 1H), 3.89 (s, 2H), 3.66 (t, J= 4.6 
Hz, 4H), 2.46 (t, J = 4.6 Hz, 4 H), 2.36 (s, 3H)  
13C NMR (101 MHz, CDCl3) δ 144.21, 144.03, 133.58, 133.20, 130.00, 128.61, 
127.90, 122.62, 121.67, 116.67, 115.82, 66.96, 53.19, 51.96, 18.54. 
LRMS EI (m/z): [M+] calc’d for C19H20ClN3O 341.13, 342.0 
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Characterization of Compound 3.15 
 
1H NMR (400 MHz, CDCl3): δ 8.58 (s, 1H), 7.74 – 7.69 (m, 2H), 7.52 (d, J = 9.5 Hz, 
1H), 7.45 – 7.41 (m, 2H), 7.29 (dd, J = 9.5, 1.9 Hz, 1H), 3.92 (s, 2H), 3.68 (t, J = 4.6 
Hz, 4H), 2.46 (t, J = 4.6 Hz, 4H). 
13C NMR (101 MHz, CDCl3): δ 144.94, 143.56, 134.11, 132.45, 130.03, 128.78, 
128.22, 125.38, 117.96, 116.48, 106.73, 66.89, 53.21, 52.04. 
LRMS EI (m/z): [M+] calc’d for C18H17BrClN3O 405.02, 407.00 
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Characterization of Compound 3.16 
 
1H NMR (400 MHz, CDCl3): δ 8.40 (d, J = 7.0 Hz, 1H), 7.72 – 7.66 (m, 2H), 7.62 (d, 
J = 9.1 Hz, 1H), 7.59 – 7.55 (m, 2H), 7.25 – 7.20 (m, 1H), 3.93 (s, 2H), 3.66 (t, J = 4.6 
Hz, 4H), 2.46 (t, J = 4.6 Hz, 4H). 
13C NMR (101 MHz, CDCl3): δ 145.15, 144.19, 133.45, 131.62, 130.36, 125.18, 
124.80, 122.00, 117.35, 116.10, 112.07, 66.93, 53.19, 52.03. 
LRMS EI (m/z): [M+] calc’d for C18H18BrN3O 371.06, observed 371.10 
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Characterization of Compound 3.17 
 
1H NMR (300 MHz, CDCl3): δ 8.28 (d, J = 7.1 Hz, 1H), 7.69 (d, J = 8.6 Hz, 2H), 
7.58 (d, J = 8.5 Hz, 2H), 7.38 (s, 1H), 6.68 (d, J = 6.7 Hz, 1H), 3.91 (s, 2H), 3.67 (t, J 
= 4.6 Hz, 4H), 2.47 (t, J = 4.6 Hz, 4H), 2.43 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 145.60, 143.86, 135.79, 133.63, 131.58, 130.31, 
124.38, 121.84, 115.71, 115.52, 114.73, 66.97, 53.17, 52.03, 21.38. 
LRMS EI (m/z): [M+] calc’d for C19H20BrN3O 385.08, observed 385.10   
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Characterization of Compound 3.18 
 
1H NMR (400 MHz, CDCl3): δ 8.59 (s, 1H), 7.69 – 7.64 (m, 2H), 7.62 – 7.57 (m, 
2H), 7.53 (dd, J = 9.5, 0.8 Hz, 1H), 7.29 (dd, J = 9.5, 1.9 Hz, 1H), 3.93 (s, 2H), 3.69 
(t, J = 4.5 Hz, 4H), 2.47 (t, J = 4.5 Hz, 4H). 
13C NMR (101 MHz, CDCl3): δ 144.93, 143.56, 132.89, 131.72, 130.31, 128.24, 
125.37, 122.35, 117.95, 116.49, 106.75, 66.88, 53.20, 52.02. 
LRMS EI (m/z): [M+] calc’d for C18H17Br2N3O 448.97, observed 451.00 
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Characterization of Compound 3.19 
 
1H NMR (400 MHz, CDCl3):) δ 8.59 (s, 1H), 7.71 – 7.61 (m, 2H), 7.52 (d, J = 9.5, 
1H), 7.33 – 7.19 (m, 3H), 3.95 (s, 2H), 3.68 (t, J = 4.6 Hz, 4H), 2.46 (s, 4H), 2.41 (s, 
3H). 
13C NMR (101 MHz, CDCl3): δ 146.18, 143.46, 137.86, 131.02, 129.26, 128.67, 
127.77, 125.41, 117.81, 116.06, 106.37, 66.93, 53.19, 52.15, 21.29. 
LRMS EI (m/z): [M+] calc’d for C19H20BrN3O 385.08, observed 385.10 
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Characterization of Compound 3.21 
 
1H NMR (400 MHz, CDCl3): δ 8.57 (s, 1H), 7.73 – 7.67 (m, 2H), 7.51 (d, J = 9.4 Hz, 
1H), 7.28 – 7.24 (m, 1H), 7.03 – 6.96 (m, 2H), 3.94 (s, 2H), 3.86 (s, 3H), 3.69 (t, J = 
4.6 Hz, 4H), 2.47 (t, J = 4.6 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 159.54 , 145.98 , 143.41 , 130.00 , 127.71 , 126.45 , 
125.31 , 117.71 , 115.73, 113.99 , 106.31 , 66.93 , 55.30 , 53.20 , 52.15 . 
LRMS EI (m/z): [M+] calc’d for C19H20BrN3O2 401.07, observed 403.10 
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Characterization of Compound 3.22 
 
1H NMR (400 MHz, CDCl3): δ 8.90 (s, 1H), 8.27 (d, J =7.6 Hz, 1H), 8.22 (d. J = 6.9 
Hz, 1H) , 8.19 (d, J = 8.39, 1H ) 7.61 (t, J = 8.0 Hz, 1H), 7.04 (d, J = 6.8, 1H), 6.79 (t, 
J = 6.9 Hz, 1H), 3.91 (s, 2H), 3.70 (t, J = 4.6 Hz, 4H), 2.65(s, 3H), 2.52 (t, J = 4.6 Hz, 
4H). 
13C NMR (101 MHz, CDCl3) δ 148.44 , 145.67, 142.39, 136.60 , 134.65 , 129.37 , 
127.64 , 123.88 , 123.79 , 122.43 , 122.24 , 117.55 , 112.60 , 66.91 , 53.11 , 51.75 , 
17.05 . 
LRMS EI (m/z): [M+] calc’d for C19H20N4O3 352.15, observed 352.20 
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